WILMINGTON, Mass.--(BUSINESS WIRE)--CuriRx, Inc., specializing in providing drug product development services, is pleased to announce that they have been awarded a 5-year contract with the National Cancer Institute ("NCI") under solicitation number N02CM37007-11, Contract# HHSN261201300034I, entitled "Development and Production of Parenteral Dosage Forms for Clinical Studies" on September 20th 2013. The primary objective of this project is to develop and produce pharmaceutically acceptable parenteral dosage forms of cancer drugs for human use. The Development Therapeutics Program (DTP) of the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis (DCTD) will provide promising new agents with activity against cancer for development and production as parenteral products.
"We are very pleased to be awarded this contract and opportunity to work with the NCI," said Indu Javeri, CuriRx's President and Chief Executive Officer. "This gives CuriRx the opportunity to make an impact on human healthcare in the field of cancer research through novel oncogenic drug formulation and provide much needed therapies for cancer patients."
CuriRx, Inc., based in Wilmington, MA is a privately held contract research organization (www.curirx.com). CuriRx provides product development services including analytical development, preformulation, formulation and lyophilization dosage form development for pharmaceuticals (small molecule including oncology compounds), peptides, biopharmaceuticals (large molecules), antibodies (conjugated antibodies), generics, vaccines and biosimilars products.